Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: A matched case-control study

Espoir Bwenge Malambaka[1,2], Patrick Musole Bugeme[1,2], Chloe Hutchins[3], Hanmeng Xu[1], Juan Dent Hulse[1], Maya N. Demby[1], Karin Gallandat[3], Jaime Mufitini Saidi[4], Baron Bashige Rumedeka[1,4], Moïse Itongwa[1], Esperance Tshiwedi-Tsilabia[5], Faida Kitoga[5], Tavia Bodisa-Matamu[5], Hugo Kavunga-Membo[5,6], Justin Bengehya[7], Jean-Claude Kulondwa[7], Amanda K Debes[8], Nagède Taty[9], Elizabeth C. Lee[1], Octavie Lunguya[6,10], Justin Lessler[1,11,12], Daniel T Leung[13,14], Oliver Cumming[3], Placide Welo Okitayemba[9], Daniel Mukadi-Bamuleka[5,6,10], Jackie Knee[3], Andrew S Azman[1,15,16*]

[1]*Department of Epidemiology, Johns Hopkins University, Baltimore, MD 21205, USA*

[2]*Centre for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo*

[3]*Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK*

[4]*Ministère de la Santé Publique, Zone de Santé d'Uvira, Democratic Republic of Congo*

[5]*Rodolphe Merieux INRB-Goma Laboratory, Goma, North-Kivu, Democratic Republic of the Congo*

[6]*Institut National de Recherche Biomédicale, INRB, Kinshasa, Democratic Republic of the Congo*

[7]*Ministère de la Santé Publique, Hygiène et Prévention, Division Provinciale de la Santé Publique du Sud-Kivu, Democratic Republic of the Congo*

[8]*Department of International Health, Johns Hopkins University, Baltimore, MD 21205, USA*

[9]*PNECHOL-MD, Community IMCI, Ministry of Health, Democratic Republic of the Congo*

[10]*Service of Microbiology, Department of Medical Biology, University of Kinshasa, Kinshasa, Democratic Republic of the Congo*

[11]*University of North Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

[12]*Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

[13]*Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, Utah, USA*

[14]*Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake City, Utah, USA*

[15]*Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland*

[16]*Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland*

* Correspondence to:

Dr Andrew S Azman,
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
Johns Hopkins University, Baltimore, MD 21205, USA
azman@jhu.edu

Abstract

Background

A global shortage of cholera vaccines has increased the use of single-dose regimens, rather than the standard two-dose regimen. There is limited evidence on single-dose protection, particularly in children. In 2020, a mass vaccination campaign resulting in largely single dose coverage, was conducted in Uvira, an endemic urban setting in eastern Democratic Republic of the Congo. We examined the effectiveness of a single-dose of the oral cholera vaccine Euvichol-plus in this high-burden setting.

Methods

We recruited medically attended confirmed cholera cases and age-, sex-, and neighborhood-matched community controls during two distinct periods after mass vaccination, October 2021 to March 2022 (12-17 months post-vaccination) and October 2022 to May 2023 (24-31 months post-vaccination). The odds of vaccination in cases and controls were contrasted in conditional logistic regression models to estimate unadjusted and adjusted vaccine effectiveness.

Findings

We enrolled 434 confirmed cases and 1562 matched controls during the two study periods with 21.7% of cases being under five years old at the time of vaccination. The adjusted single-dose VE was 52% (95% CI: 32·3–66) 12-17 months post-vaccination and 40·8% (95% CI: 8·6–61·7) 24-31 months post-vaccination. While protection in the first 17 months post-vaccination among those under five years old was similar to older individuals, after two years under-five-year-olds appeared to be less protected (adjusted VE 31.9%; 95% CI: -58.5–70.8) though with large uncertainty.

Interpretation

A single-dose of Euvichol-Plus provided substantial protection against medically attended cholera for at least 31 months post-vaccination in this cholera endemic setting though our limited sample size in under-five-year-olds limited our ability to make strong conclusions about protection in this age group.

Funding

Wellcome Trust and Gavi (GAVI-RFP-2019-062).

Introduction

Safe water, sanitation, and hygiene (WASH) is the cornerstone of cholera prevention and control. While universal access to safely-managed WASH services remains the ultimate priority, this is likely a distant prospect.[1] Killed whole-cell oral cholera vaccine (kOCV) is an effective short-term intervention to reduce cholera risk in high-burden settings with limited WASH coverage and is a key component of the global roadmap to end cholera.[2] kOCVs are typically delivered as a two-dose regimen that provides protection for at least three years.[3,4] In a meta-analysis of kOCV protection, estimated two-dose efficacy was 58% (95% CI: 42 to 69), over an average of 28 months post-vaccination. Lower protection was noted among young children.[3]

The Euvichol-Plus® vaccine (Eubiologics, Seoul, Republic of Korea) is currently the only WHO-prequalified kOCV manufactured and included in the global stockpile after the Shanchol® (Shantha Biotechnics, Hyderabad, India) ceased production in 2023.[5] Euvichol-Plus® is considered a bioequivalent of Shanchol®.[6] Almost all evidence of kOCVs clinical protection is based on the studies carried out on Shanchol®,[7–9] although one observational study explored the protection conferred by a Euvichol-Plus® two-dose regimen.[10]

Demand for kOCVs outstripped the global supply in 2022, with only 23·5 million doses distributed out of the 33 million requested.[11] In late 2022, the International Coordinating Group, which manages the global emergency stockpile for cholera vaccines, suspended the provision of the standard two-dose regimen in emergency vaccination campaigns, replacing it with a single-dose regimen due to limited vaccine supply.[12] However, there are limited data on the protection offered by one dose of kOCV over extended periods (>12 months) or among children 1-4 years old.

Only a few studies have estimated single-dose protection in the general population, with point estimates suggesting short-term protection up to 16 months after vaccination in Haiti, though with large uncertainty. [7–9,13–16] A randomized trial in Bangladesh, the only study to provide age-stratified estimates of single-dose protection, suggested that Shanchol® conferred no protection in 1-4 year olds in the first six months post-vaccination, despite significant protection in older individuals for at least two years.[17,18]

In late 2020, the Ministry of Health of the Democratic Republic of the Congo (DRC) conducted a mass vaccination campaign of Euvichol-Plus® in the city of Uvira in theSouth Kivu province. The estimated coverage of the vaccination campaigns was low, and as most vaccinated individuals reported receiving one dose only, we assessed effectiveness of a single dose of kOCV during outbreaks that occurred 12-17 and 24-31 months after vaccination.

Study design, setting and vaccination campaigns

We conducted a matched case-control study in Uvira, a city of approximately 280,000 inhabitants on the northwestern shore of Lake Tanganyika with sporadic armed conflict, socio-

political instability and population displacement. Cholera cases are detected year-round in Uvira since 1978, often with distinct seasonal peaks and notable historical outbreaks.[19,20] Household surveys conducted in 2016/17 in Uvira indicated surface water as the main drinking water source for 37.2% of households,[21] and in areas close to the rivers and with the lowest tap water availability, >80% of households use drinking water contaminated with *Escherichia coli.*[22] The same surveys estimated that about half (48.2%) of the population relied exclusively on tap water for drinking needs [21], and a recent study showed that between 2017 and 2021, the water service quality remained suboptimal, or deteriorated in many parts of the city.[23 20]

In April 2020, severe flooding caused at least 54 deaths, the displacement of approximately 80,000 people, and substantial damage to housing and WASH infrastructure in Uvira, prompting the Ministry of Health to conduct emergency cholera vaccination campaigns.[24] Vaccination took place in two rounds, from 29 July to 8 August and 1-8 October 2020 targeting all individuals in Uvira one year and older. The campaigns included door-to-door vaccination for five days, followed by vaccination offered through health facilities. While two rounds of vaccination were implemented, in a representative household survey we conducted 11 months after vaccination, 23.1% (95% CI: 20-27%) of the participants reported receiving two doses of the vaccine and 32% (95% CI: 38-36%) reported receiving one dose. No kOCV has been administered in this population between these campaigns and the end of our study period, May 2023.

Clinical cholera surveillance system in Uvira

Our study is based on enhanced clinical surveillance of cholera implemented at the two official health facilities designated to treat cholera patients in Uvira, the cholera treatment centre at the Uvira General Referral Hospital and the cholera treatment unit at the Kalundu CEPAC health centre (henceforth, “CTCs”). We attempted to identify and recruit all patients at least 12 months old with acute watery diarrhoea within the 24 hours prior to the admission to the CTCs (referred to as ‘suspected cholera’). Trained healthcare staff collected rectal swabs and stools from participants. Rectal swabs were enriched in alkaline peptone water (APW) for 6-18 hours depending on patient admission time. Specimens were tested for *V. cholerae* by rapid diagnostic tests (RDTs) onsite, and by culture using standard methods (Appendix) at either an in-country reference laboratory, the Laboratoire Rodolphe Mérieux de l’Institut National de Recherche Biomédicale (INRB), in Goma (from October 2021 to September 2022), or at the onsite study laboratory (from September 2022 onward). As PCR for *V. cholerae* O1 was not available at either study laboratory in DRC, we shipped stool specimens (stool spotted on dry filter papers) for cases enrolled between October 14, 2021 and May 04, 2022 to Johns Hopkins University for PCR detection of toxigenic *V. cholerae* O1 following published methods.[25]

Selection of cases and controls

Two cholera outbreaks occurred after mass vaccination, and we recruited cases during each outbreak, forming two distinct study periods (Figure 1). From 21 November 2022 to 24 January

2023, we retrospectively recruited controls for patients admitted to CTCs during the first outbreak (14 October 2021 to 10 March 2022), approximately 12-17 months after the second round of mass vaccination campaigns (Study Period 1). Between 17 October 2022 and 9 May 2023, we recruited controls for cases as they were admitted to the CTCs, 24-31 months after vaccination (Study Period 2).

Study Period 1 (SP1) included all consenting suspected cases who were at least 12 months old during the vaccination campaigns, living in Uvira for the two weeks prior to admission to the CTC and during the 2020 vaccination campaigns, and who tested positive for cholera by culture and/or PCR. We attempted to recruit four controls per case, using high-resolution satellite imagery (Appendix) to identify potential control households on the same avenue (smallest administrative unit in Uvira) as the case household. Control households were then selected by simple random spatial sampling of digitized residential structures. Controls were eligible for enrollment if: (1) they matched the case age group (1-4, 5-9, 10-19, 20-39, 40-59 or ≥60 years old) and sex, (2) had not been admitted for acute watery diarrhoea or cholera in the three years prior to the case admission, (3) were living in Uvira in the two weeks prior to case admission, (4) were living in Uvira at the time of the 2020 kOCV campaign and were eligible to be vaccinated, and (5) none of their household members reported being admitted to a formal health facility (as opposed to pharmacies, prayer homes or traditional healers) for acute watery diarrhoea or cholera in the four weeks prior to case admission.

During Study Period 2 (SP2), the case definition included the same age and residence criteria as in SP1, but cases had to test positive with both APW-enriched rapid diagnostic test (RDT) and culture (performed at the onsite laboratory). We used enriched RDT results to help prioritize control recruitment due to limited human resources during the outbreak. In contrast to SP1, we conducted a home visit within three days of hospital discharge to investigate the living and WASH conditions in each case's household and ascertain the vaccination status outside the hospital environment (as done with the controls). We excluded patients who died during hospitalization and those whose residence could not be found during home visits. As in SP1, four neighborhood controls were recruited from four randomly selected households near the case household, though during this study period we selected households using the 'right-hand' rule (Appendix). In addition to the recruitment criteria used in SP1, controls were eligible for enrolment in SP2 if their household matched that of the case by size (≤5 individuals, 6-10 individuals, and >10 individuals) and had at least one child below five years of age when the case household had one.

Vaccination status ascertainment and potential confounding variables

Study staff administered structured questionnaires to all cases and controls (or their parent/guardian) to capture demographics, household conditions, potential confounding variables and vaccination status. Before asking each case or control whether they were vaccinated, study staff showed them photos of the vaccine vials and of someone taking the vaccine in addition to

explaining when and how the vaccines were delivered in Uvira, and how these may differ from other campaigns and routine vaccines. Participants reporting vaccination were asked the number of doses and when and where each one was taken. We also used vaccination cards to verify the vaccination status whenever possible. In SP1, vaccine-related questions were asked to cases in the clinic and in SP2 they were asked both in the clinic and a subsequent home visit. Any differences in the vaccination status reporting between the clinic and household interviews were solved through a third interview at the case's household followed by a review of the data, discussion, and consensus within the study team. We identified potential confounders based on a causal directed acyclic graph developed before the start of the study and attempted to measure these through the interviews.

Statistical analyses

The characteristics of case and control participants were compared using the standardized mean difference (SMD), which is the absolute difference in mean values of a variable between cases and controls divided by the pooled standard deviation. In addition, we calculated p-values from univariate conditional logistic regression models with case-control status as the dependent variable. In the primary analysis, we compared the odds of being vaccinated with a single kOCV dose between cases and controls using conditional logistic regression models. Those reporting to have received 2 or more doses were dropped from the primary analyses. The vaccine effectiveness (VE) was calculated as one minus the estimated odds ratio of having received a single dose of vaccine, between cases and controls. To produce consistent age-group specific and overall estimates of effectiveness across all ages, the conditional logistic regression model included an interaction term for age group (1-4 vs. ≥5) and the vaccination status. We derived the overall VE estimate based on a linear combination of parameters from the two age groups, weighted by the proportion of cases within each, and estimated simultaneous confidence intervals with the ghlt function in the multcomp R package.[26] For combined estimates (SP1/2) and those from SP1, we incorporated age as a continuous variable (separately by the two age groups) to adjust for potential confounding. For SP2, estimates were adjusted for a set of potential confounders including age and household size (second degree polynomial), household wealth index (as a continuous variable) derived from a principal component analysis of household assets ownership (Appendix), type of sanitation facility, whether the participant used a toilet shared by multiple households compared to using a private toilet, drinking water sources, and availability of a hand washing facility and soap. For continuous variables, we explored models using polynomials and restricted cubic splines, and compared them using Akaike Information Criterion (AIC). We also fit three alternative models with different sets of covariates to assess the robustness of the estimates (Appendix). In a secondary analysis, we estimated the VE for at least one dose and two doses of kOCV compared to the unvaccinated group. While we primarily relied on point estimates and 95% confidence intervals (CI) to assess the weight of evidence, we considered p-values statistically significant when they were less than 0.05. Analyses were performed in R (version 4.2.3).

Ethical considerations

Ethical approvals were obtained from Institutional Review Boards of the Johns Hopkins Bloomberg School of Public Health (IRB00015785), the London School of Hygiene & Tropical Medicine (25365) and the École de Santé Publique at the University of Kinshasa (ESP/CE/65/2021). Written informed consent was obtained from all participants ≥18 years, with written assent from those <18 years in addition to written consent from their parent/guardian.

Role of the funding source

The funders of the study had no role in study design, data analysis, interpretation, preparation of this manuscript, or the decision to publish.

Results

Cholera incidence in Uvira and recruitment of study participants

We recruited 434 unique confirmed cholera cases and 1562 matched controls during the two study periods (Figure 1), with 38·5% of cases enrolled in the second period. The median age of participants at the time of the vaccination campaigns was 14·0 (interquartile range 5·0, 30·0) years and 22·4% were under five years old (Table 1). Fifty six percent of cases were recorded as severely dehydrated on admission. Cases were significantly older during the first study period compared to the second period ($p<0.001$) though they all had similar dehydration status (Table S2). Of the 309 culture positive isolates, 275 (89·0%) were serotype Ogawa, the rest were Inaba, including 4·8% (n=8/167) Inaba in SP1 and 18·3% (n = 26/142) Inaba in SP2.



Figure 1. Number of cholera cases admitted to cholera treatment facilities in Uvira. Panels A (Study Period 1) and B (Study Period 2) illustrate the cumulative number of confirmed cases in each study period by neighborhood (avenue) across the city, with the locations of the two health facilities where patients were recruited shown as dots. There were 14 cases living in neighboring communities outside the city boundaries that were included in Study Period 2. The second outbreak (Study Period 2) started in the northern part of the city and spread to a refugee camp where many residents were admitted to the CTC but not included in the study as they were not living in Uvira at the time of vaccination. Panel C illustrates the epidemic curve of suspected and confirmed cholera cases admitted to the cholera treatment center (CTC) at the Uvira General Referral Hospital and the cholera treatment unit (CTU) at the Kalundu CEPAC health center. Cholera was confirmed by culture or PCR (Study Period 1), or by APW-enriched RDT and culture (Study Period 2). Among the 183 suspected cases that were detected before SP1 (in grey), 146 (79·8) were tested for *Vibrio cholerae* O1 by enriched RDT with 37 (25·3%) testing positive.

Overall, 22·1% of cases reported receiving one dose of kOCV and 65·7% were unvaccinated. In comparison, 33·7% of matched controls reported receiving a single dose of kOCV and 53·3% were unvaccinated. Only 13·6% of vaccinated participants were able to show a vaccination card and 12·8% reported having received two doses of the vaccine (Table 1).



Figure 2. Flow chart of participant recruitment. Cases with unavailable culture results are those for which 1) suspected colonies were isolated, 2) with positive oxidase test at the field laboratory, 3) missing agglutination results due to an antiserum stockout, 4) and/or in which attempts to revitalize *Vibrio cholerae* O1 strains at the reference laboratory in Goma were unsuccessful.

Table 1: Characteristics of participants by case and control status.

Characteristic	**Overall**, N = 1,996	**Cases**, N = 434	**Controls**, N = 1,562	**P-value**	**SMD**

Age group* (years)					0.052
1-4	448 (22.4%)	94 (21.7%)	354 (22.7%)	Reference	
5-9	344 (17.2%)	81 (18.7%)	263 (16.8%)	0.5329	
10-19	467 (23.4%)	99 (22.8%)	368 (23.6%)	0.5238	
20-39	379 (19.0%)	82 (18.9%)	297 (19.0%)	0.4136	
40-59	240 (12.0%)	53 (12.2%)	187 (12.0%)	0.6040	
≥60	118 (5.9%)	25 (5.8%)	93 (6.0%)	0.4032	
Sex					0.014
Female	963 (48.2%)	207 (47.7%)	756 (48.4%)	Reference	
Male	1,033 (51.8%)	227 (52.3%)	806 (51.6%)	0.3057	
Vaccination status					0.274**
Not Vaccinated	1,118 (56.0%)	285 (65.7%)	833 (53.3%)	Reference	
One Dose	622 (31.2%)	96 (22.1%)	526 (33.7%)	<0.0001	
Two Doses	256 (12.8%)	53 (12.2%)	203 (13.0%)	0.0928	
Vaccination card unavailable	119 (13.6%)	18 (12.4%)	101 (13.8%)	0.4340	0.042

Data are n (%). * Age group refers to the age on the first day of the second mass vaccination campaign round (1 October 2020). **Standard mean difference (SMD) between participants who reported receipt of one dose of kOCV and those who were not vaccinated.

Additional data on socio-demographic and household characteristics were collected in SP2 (Table 2, Table S4). Cases were more likely to report drinking water from an unimproved source compared to controls (odds ratio [OR] 1·82; 95% CI 1·15-2·86). Likewise, cases were more likely to use toilets shared by multiple households than controls (OR 1·59; 95% CI 1·10-2·30). Although likely an artifact of hygiene kit distribution that focused on case households, we found that cases were more likely to live in households with soap and water available for handwashing (OR 1·85; 95% CI 1·20–2·85).

Table 2. Characteristics of study participants in the vaccine effectiveness analysis 24-31 months after vaccination (Study Period 2)

Characteristic	**Overall**, N = 814	**case**, N = 167	**control**, N = 647	**P-value**	**SMD**
Age (years), median (IQR)	9.0 (4.0, 23.0)	8.0 (4.0, 22.5)	10.0 (4.0, 23.5)		0.032
Age group (years)*					0.160
1-4	235 (28.9%)	44 (26.3%)	191 (29.5%)	Ref.	
5-9	176 (21.6%)	44 (26.3%)	132 (20.4%)	0.05	
10-19	161 (19.8%)	30 (18.0%)	131 (20.2%)	0.85	
20-39	130 (16.0%)	26 (15.6%)	104 (16.1%)	0.98	
40-59	71 (8.7%)	16 (9.6%)	55 (8.5%)	0.78	
≥60	41 (5.0%)	7 (4.2%)	34 (5.3%)	0.77	
Sex					0.035
Female	406 (49.9%)	81 (48.5%)	325 (50.2%)	Ref.	
Male	408 (50.1%)	86 (51.5%)	322 (49.8%)	0.06	
Education attainment					0.150
None or primary	65 (27.2%)	13 (31.0%)	52 (26.4%)	Ref.	
Lower secondary	36 (15.1%)	6 (14.3%)	30 (15.2%)	0.75	
Upper secondary	120 (50.2%)	19 (45.2%)	101 (51.3%)	0.40	

Bachelor or higher	18 (7.5%)	4 (9.5%)	14 (7.1%)	0.56	
Occupation					0.126
No work	92 (11.3%)	23 (13.8%)	69 (10.7%)	Ref.	
Preschool children	176 (21.6%)	39 (23.4%)	137 (21.2%)	0.93	
Students	354 (43.5%)	70 (41.9%)	284 (43.9%)	0.57	
Informal work	154 (18.9%)	28 (16.8%)	126 (19.5%)	0.20	
Salaried	38 (4.7%)	7 (4.2%)	31 (4.8%)	0.40	
Household size, median (IQR)	7.0 (6.0, 9.0)	7.0 (5.0, 9.0)	7.0 (6.0, 9.0)	0.35	0.032
Children under five years old in the household					0.111
Zero	192 (23.6%)	42 (25.3%)	150 (23.2%)	Ref.	
1-2	536 (65.9%)	103 (62.0%)	433 (66.9%)	0.43	
≥3	85 (10.5%)	21 (12.7%)	64 (9.9%)	0.34	
Missing	1	1	0		
Living in household with improved drinking water source	538 (66.7%)	100 (60.2%)	438 (68.4%)	0.0098	0.172
Living in household with shared toilet					0.2130
Private	375 (46.1%)	63 (37.7%)	312 (48.2%)	Ref.	
Shared	439 (53.9%)	104 (62.3%)	335 (51.8%)	0.0140	
Living in household with improved toilet	495 (60.8%)	102 (61.1%)	393 (60.7%)	0.87	0.007
Soap and water available for handwashing	355 (43.6%)	85 (50.9%)	270 (41.7%)	0.0054	0.185
Electricity in household	312 (38.3%)	53 (31.7%)	259 (40.0%)	0.0279	0.174
Wealth index, median (IQR) ***	-2.2 (-45.6, 35.4)	-15.7 (-51.0, 30.8)	-2.2 (-45.6, 36.8)	0.0236	0.167
Vaccination status					0.222
Not Vaccinated	439 (53.9%)	100 (59.9%)	339 (52.4%)	Ref.	
One Dose	270 (33.2%)	42 (25.1%)	228 (35.2%)	0.0198	
Two Doses	105 (12.9%)	25 (15.0%)	80 (12.4%)	0.97	
Vaccination card available	56 (14.9%)	11 (16.4%)	45 (14.6%)	0.41	0.050

*Age group refers to the age on the first day of the second mass vaccination campaign round (01 October 2020). **The question about education attainment was only asked to individuals aged ≥ 18 years. *** Wealth index was multiplied by 100. The higher the wealth index the richer the household. **** The distribution of age and sex of the cases and controls does not match perfectly because the number of controls included for each case varied slightly due to enrolled controls either not meeting the eligibility criteria (e.g., not living in Uvira during vaccination) or not recalling their vaccination status.

Combining data from both study periods, 12-31 months post-vaccination, we estimated an unadjusted and adjusted single-dose VE of 45·9% (95% Confidence Interval [CI] 29·5–58·5) and 44·4% (95% CI 27·3–57·4).

In SP1, 12–17 months after vaccination, we estimated an unadjusted and adjusted single-dose VE of 51·7% (95% CI: 31·8–65·8) and 48·2% (95% CI: 26·4–63·5). In SP2, 24–31 months after vaccination, we estimated an unadjusted VE of 35·2% (95% CI: 1·6–57·4) and an adjusted VE of

45·6% (95% CI: 14·1–65·5). The adjusted VE for 1–4-year-olds was 47·4% (95% CI: -25.0·2–77·2) in SP1 and 31·9% (95% CI: -58·5–70.8) in SP2, suggesting the potential of a more rapid decline in protection among this age group (Table 3).

Table 3. Effectiveness of a single dose of oral cholera vaccine, 12-17 months and 24-31 months after vaccination campaigns.

Population	Cases (effective n†)	Controls (effective n†)	Unadjusted VE (95% CI)	Adjusted VE* (95% CI)
12-31 months after vaccination				
Overall	375 (300)	1359 (554)	45.9% (29.5–58.5)	44.4% (27.3–57.4)
1-4 years	74 (56)	264 (117)	46.4% (8.0–68.8)	39.4% (-6.6–65.5)
≥5 years	296 (228)	994 (415)	45.8% (27–59.7)	45.7% (26.6–59.9)
12-17 months after vaccination (Study Period 1)				
Overall	233 (184)	792 (332)	51.7% (31.8–65.8)	48.2% (26.4–63.5)
1-4 years	38 (27)	137 (55)	47.9% (-17.8–76.9)	47.4% (-25.0–77.9)
≥5 years	192 (150)	614 (267)	52.6% (30.9–67.4)	48.3% (24.2–64.8)
24-31 months after vaccination (Study Period 2)				
Overall	142 (116)	567 (222)	35.2% (1.6–57.4)	45.6% (14.1–65.5)
1-4 years	36 (29)	127 (62)	44.3% (-15.0–73.0)	31.9% (-58.5–70.8)
≥5 years	104 (78)	380 (148)	31.2% (-12–57.7)	50.3% (15.7–70.7)

*In SP1 and in analyses combining data from both study periods, we only adjusted for age as a continuous variable. †Effective number of cases and controls is the sample size that effectively contributes to estimates of effectiveness in the conditional logistic regression models. Those participants in matched case-control sets where all people have the same vaccination status do not contribute to the estimates, nor do those who either do not know their vaccination status or the number of doses they received.

In secondary analyses, we estimated the adjusted cumulative VE across both study periods for at least one dose of kOCV to be 39·9% (95% CI: 24·2–52·4, Table S6). This estimate, which includes those who report having received two doses of kOCV, is slightly lower than our single-dose estimate and is driven by unexpectedly low, though uncertain, estimates for 1-4-year-olds in SP1 (Table S3). We were unable to reliably estimate two-dose VE due to a limited effective sample size, with post-hoc power calculations suggesting we had 16.4% power to detect significant vaccine protection (Appendix).

Discussion

We found that a single dose of Euvichol-Plus kOCV provided protection against cholera for at least the 31-month period post-vaccination. Our study provides unique, policy-relevant insights into kOCV protection as we estimated single-dose effectiveness from the only available and most widely used cholera vaccine today, including estimates of effectiveness for 1-4-year-olds and at discrete time windows after vaccination. Our results suggest that at least in cholera endemic areas like Uvira, the use of one kOCV dose may provide significant protection on the scale of years rather than just months.

To date, one randomized trial[17,18] and seven observational studies have included estimates of one-dose protection of kOCVs.[7–9,13–15,27] Most of these studies have been short-term estimates of protection measured for just a few months after vaccination and showed similar levels of protection to two doses on this timescale. Two notable exceptions where protection was measured over a longer period include a randomized trial in Bangladesh and a case-control study in Haiti, both using Shanchol®. The Bangladesh trial was conducted for two years and estimated 54% (95% CI: 16 to 75) efficacy in the first year and 67% (43 to 81) in the second year post-vaccination among those five years and older.[17] Secondary analyses from a case-control study in Haiti predicted that a single dose of kOCV (Shanchol®) would confer 58% (95% CI: 4 to 82%) protection at 16 months post-vaccination, with the confidence intervals including zero protection from 17-months post-vaccination and onward.[14] Our results are consistent with these previous studies in showing significant protection for the overall population for longer than a year, though it is important to note that Uvira, like Haiti (at the time of the study) and Bangladesh, is endemic for cholera so the first dose may have acted as a booster for previously exposed individuals. Furthermore, it is possible that previous exposures to enterotoxigenic *Escherichia coli*, which has been identified among diarrhoea cases in Uvira and has a antigenically similar toxin to toxigenic *V. cholerae*, could contribute to background immunity to severe disease in these settings.[29] More work is needed to characterize the epidemiologic settings where one dose may provide comparable levels of protection to the full regimen, and might include leveraging historic incidence rates of cholera or, perhaps, population-level immunologic measures of previous exposures.[30]

Before this study, only one estimate of single-dose protection of a kOCV in 1-4-year-olds had been published. This trial, in Bangladesh, suggested that young children did not benefit from a single dose of Shanchol, even during the first six months post-vaccination.[17,18] While our estimates of Euvichol-Plus effectiveness in this age group come with large uncertainty, the similar point estimates between 1-4 year olds and older individuals at 12-17 months post-vaccination suggests that they may have similar protection over this time frame. This observation is in line with studies showing similar levels of protection after natural infection between the two age groups.[31] Conflicting estimates between young children and older individuals have also been observed in kOCV studies with the full dose regimen, though there are only a handful of studies that present age-stratified estimates. Although most studies have found lower effectiveness in young children, the difference in protection has been highly variable with large uncertainty (e.g., ranging from no apparent difference in Vietnam after 10 months,[32] to 73% lower protective efficacy among children in Bangladesh over 6 months post-vaccination[18]). If children in Uvira were indeed protected by a single dose of Euvichol-Plus, the contrast with other studies could be explained by several factors including pre-existing population immunity and season of vaccination as shown with other diseases,[33] differences both in gut microbiota composition and in prevalence of enteropathy.[34,35]

While the focus of the study was to understand the direct effectiveness of oral cholera vaccine, our analysis of potential risk factors highlighted key differences between cases and matched controls. Our results confirm the associations between cholera and markers of poverty, like using a shared latrine, using an unimproved source for drinking water and not having electricity in the household. While kOCV provides protection against cholera, tackling fundamental risk factors like access to safe water and sanitation are needed to sustainably control the disease.

This study comes with several limitations. First, like many previous kOCV effectiveness studies, the vaccination status was self-reported,[7,14,15] and only 18 cases were able to provide a vaccination card. Measurements of the number of doses received months to years after a mass vaccination campaign is prone to recall bias, particularly in a place like Uvira where mass vaccination campaigns with different antigens are common. To minimize biases in classification of vaccination status, we used visual aids and a series of structured questions, and hospital and study staff reassured patients that their responses to the study questions would in no way affect their care. Though enumerators were not blinded to the vaccination status of the cases while enrolling their matched controls, the vaccine coverage among controls was like that measured in community coverage surveys. Furthermore, sensitivity analyses restricted to only those with a vaccination card revealed similar effectiveness estimates (Table S5). There were slight differences in the protocols of the case-control study in each study period, challenging the interpretability of the joint estimates from both periods. However, in sensitivity analyses simulating similar diagnostic criteria for cases in SP1 as SP2, our qualitative findings remained consistent (Table S6). The retrospective recruitment of controls for cases admitted during the SP1 precluded adjustment for individual and household factors that may have influenced cholera disease risk or vaccine acceptability and could also have led to differential recall of vaccination status among cases and their controls. Even in SP2, our VE estimates could still be confounded by unmeasured factors. Even though the number of cases under five years of age was higher than in most published VE studies, our sample size in this important age group was still small and led to wide confidence intervals around VE estimates (Table S6). Finally, we were unable to obtain reliable estimates of two dose protection partly because few cases reported receipt of two doses of kOCV due to low vaccination coverage in the population, and potentially because of uncertainty in the reporting of more than one dose of kOCV (Tables S3 and S4).

Our findings, combined with data from dose-interval studies conducted in Cameroon and Zambia[36,37], suggest that providing a second dose a year or more after the first could lead to better and longer lasting protection against cholera than the current two-dose series, at least among older children and adults. While more data are needed across different settings and for longer periods of time, our study extends the current evidence base on protection from a single-dose of kOCV, and more specifically on protection from Euvichol-Plus, the most widely used cholera vaccine available today.

Declarations

Funding

This work was supported by the Wellcome Trust and Gavi (GAVI-RFP-2019-062).

Authors' contributions

Conceptualization: EBM, ASA, JK. Data curation: EBM, JDH, HX, CH, PMB, ASA. Formal analysis: EBM, ASA. Data interpretation: EBM, ASA, JK, JL, EL. Funding acquisition: ASA, KG, OC. Investigation: EBM, PMB, CH, HX, JDH, BBR, MI, ETT, FK, TBM, AD, EL, DL, JK, ASA. Methodology: EBM, ASA, CH, JK. Project Administration: EBM, PMB, MD, DMB, HKM, CH, ASA, KG. Resources: PWO, JMS, DMB, AD, JK, OL. Software: EBM, JDH, HX, ASA. Supervision: ASA, JK. Validation: EBM, ASA. Visualization - EBM, ASA. Writing - original draft - EBM, ASA. Writing: review & editing: all authors.

Acknowledgements

We are thankful to Faraja Masema Lulela, Joël Faraja Zigashane Mashauri, Jean-Marie Masugamuhanya Cirhonda, the CTCs nurses and field investigators for their support for the data collection. We also thank the Head of the Uvira Health Zone, Dr Panzu Nimi, and the Director of the Uvira General Referral Hospital, Dr Salomon Mashupe, for their operational and administrative support throughout this study. We would also like to thank the MSF GIS Centre, including Frederic Ham and Edith Rogenhofer, for their assistance with acquiring satellite imagery data.

Data sharing

Code and data from this study are available at https://github.com/HopkinsIDD/uvira_onedose_ocv_ve.

References

1 Deshpande A, Miller-Petrie MK, Lindstedt PA, *et al.* Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. *The Lancet Global Health* 2020; **8**: e1162–85.

2 World Health Organization. Global Task Force on Cholera Control. Ending Cholera, a Global Roadmap to 2030. World Health Organization, 2017.

3 Bi Q, Ferreras E, Pezzoli L, *et al.* Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**: 1080–8.

4 Ali M, Qadri F, Kim DR, *et al.* Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial. *Lancet Infect Dis* 2021; **21**: 1407–14.

5 Burki T. Addressing the shortage of cholera vaccines. *Lancet Infect Dis* 2022; **22**: 1674–5.

6 Odevall L, Hong D, Digilio L, *et al.* The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships. *Vaccine* 2018; **36**: 6606–14.

7 Luquero FJ, Grout L, Ciglenecki I, *et al.* Use of Vibrio cholerae vaccine in an outbreak in Guinea. *N Engl J Med* 2014; **370**: 2111–20.

8 Azman AS, Parker LA, Rumunu J, *et al.* Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. *Lancet Glob Health* 2016; **4**: e856–63.

9 Grandesso F, Kasambara W, Page A-L, *et al.* Effectiveness of oral cholera vaccine in preventing cholera among fishermen in Lake Chilwa, Malawi: A case-control study. *Vaccine* 2019; **37**: 3668–76.

10 Sialubanje C, Kapina M, Chewe O, *et al.* Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case–control study in Lusaka, Zambia. *BMJ Open* 2022; **12**: e066945.

11 Bouhénia M. Overview of the OCV use in 2022. 2022; published online Oct 11. https://www.gtfcc.org/events/9th-meeting-of-the-gtfcc-working-group-on-oral-cholera-vaccine/ (accessed May 10, 2023).

12 World Health Organization. Shortage of cholera vaccines leads to temporary suspension of two-dose strategy, as cases rise worldwide. 2022; published online Oct 19. https://www.who.int/news/item/19-10-2022-shortage-of-cholera-vaccines-leads-to-temporary-suspension-of-two-dose-strategy--as-cases-rise-worldwide (accessed March 24, 2023).

13 Khatib AM, Ali M, von Seidlein L, *et al.* Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. *Lancet Infect Dis* 2012; **12**: 837–44.

14 Franke MF, Ternier R, Jerome JG, Matias WR, Harris JB, Ivers LC. Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study. *Lancet Glob Health* 2018; **6**: e1028–35.

15 Ferreras E, Blake A, Chewe O, *et al.* Alternative observational designs to estimate the effectiveness of one dose of oral cholera vaccine in Lusaka, Zambia. *Epidemiol Infect* 2020; **148**: e78.

16 Ivers LC, Hilaire IJ, Teng JE, *et al.* Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis. *Lancet Glob Health* 2015; **3**: e162–8.

17 Qadri F, Ali M, Lynch J, *et al.* Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial. *Lancet Infect Dis* 2018; **18**: 666–74.

18 Qadri F, Wierzba TF, Ali M, *et al.* Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh. *N Engl J Med* 2016; **374**: 1723–32.

19 Bugeme PM, Xu H, Hutchins C, *et al.* Cholera deaths during outbreaks in Uvira, Eastern Democratic Republic of Congo, September 2021-January 2023. bioRxiv. 2023; published online June 3. DOI:10.1101/2023.05.26.23290528.

20 Schyns C, Fossa A, Mutombo-Nfenda, *et al.* Cholera in Eastern Zaire, 1978. *Ann Soc Belg Med Trop*

1979; **59**: 391–400.

21 Jeandron A. Tap water access and its relationship with cholera and other diarrhoeal diseases in an urban, cholera-endemic setting in the Democratic Republic of the Congo. 2020; published online Dec 12. DOI:10.17037/PUBS.04659288.

22 Jeandron A, Cumming O, Kapepula L, Cousens S. Predicting quality and quantity of water used by urban households based on tap water service. *npj Clean Water* 2019; **2**: 1–9.

23 Gaiffe M, Dross C, Malembaka EB, Ross I, Cumming O, Gallandat K. A fuzzy inference-based index for piped water supply service quality in a complex, low-income urban setting. *Water Res* 2023; : 120316.

24 Gallandat K, Macdougall A, Jeandron A, *et al.* 1 Improved water supply infrastructure to reduce acute diarrhoeal diseases and 2 cholera in Uvira, Democratic Republic of the Congo: results and lessons learned 3 from a pragmatic trial. https://osf.io/na47d/download (accessed July 23, 2023).

25 Debes AK, Ateudjieu J, Guenou E, *et al.* Clinical and Environmental Surveillance for Vibrio cholerae in Resource Constrained Areas: Application During a 1-Year Surveillance in the Far North Region of Cameroon. *Am J Trop Med Hyg* 2016; **94**: 537–43.

26 Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. *Biom J* 2008; **50**: 346–63.

27 Wierzba TF, Kar SK, Mogasale VV, *et al.* Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India. *Vaccine* 2015; **33**: 2463–9.

28 Haney DJ, Lock MD, Gurwith M, *et al.* Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection. *Vaccine* 2018; **36**: 2768–73.

29 Clemens JD, Sack DA, Harris JR, *et al.* Cross-Protection by B Subunit-Whole Cell Cholera Vaccine Against Diarrhea Associated with Heat-Labile Toxin-Producing Enterotoxigenic Escherichia coli: Results of a Large-Scale Field Trial. *J Infect Dis* 1988; **158**: 372–7.

30 Azman AS, Lessler J, Luquero FJ, *et al.* Estimating cholera incidence with cross-sectional serology. *Sci Transl Med* 2019; **11**. DOI:10.1126/scitranslmed.aau6242.

31 Ali M, Emch M, Park JK, Yunus M, Clemens J. Natural Cholera Infection–Derived Immunity in an Endemic Setting. *J Infect Dis* 2011; **204**: 912–8.

32 Trach DD, Clemens JD, Ke NT, *et al.* Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. *Lancet* 1997; **349**: 231–5.

33 Moore SE, Collinson AC, Fulford AJC, *et al.* Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan. *Trop Med Int Health* 2006; **11**: 1529–41.

34 Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. *Clin Microbiol Rev* 2019; **32**. DOI:10.1128/CMR.00084-18.

35 Porras AM, Shi Q, Zhou H, *et al.* Geographic differences in gut microbiota composition impact susceptibility to enteric infection. *Cell Rep* 2021; **36**: 109457.

36 Mwaba J, Chisenga CC, Xiao S, *et al.* Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia. *Vaccine* 2021; **39**: 4516–23.

37 Ateudjieu J, Sack DA, Nafack SS, *et al.* An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon. *Am J Trop Med Hyg* 2022; **107**: 974–83.